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Abstract
OBJECTIVE—To assess depression markers (symptoms and antidepressant medicine use) in
Diabetes Prevention Program (DPP) participants and to determine whether changes in depression
markers during the course of the study were associated with treatment arm, weight change, physical
activity level, or participant demographic characteristics.
RESEARCH DESIGN AND METHODS—DPP participants (n = 3,187) in three treatment arms
(intensive lifestyle, metformin, and placebo) completed the Beck Depression Inventory (BDI) and
reported on use of antidepressant medicines at randomization and subsequently at each annual visit
(average duration in study 3.2 years).
RESULTS—On study entry, 10.3% of participants had BDI scores 311, which was used as a
threshold for mild depression, 5.7% took antidepressant medicines, and 0.9% had both depression
markers. During the DPP, the proportion of participants with elevated BDI scores declined (from
10.3% at baseline to 8.4% at year 3), while the proportion taking antidepressant medicines increased
(from 5.7% at baseline to 8.7% at year 3), leaving the proportion with either marker unchanged.
These time trends were not significantly associated with the DPP treatment arm. Depression markers
throughout the study were associated with some participant demographic factors, adjusted for other
factors. Men were less likely to have elevated depression scores and less likely to use antidepressant
medicine at baseline (9.0% of men and 17.9% of women had at least one marker of depression) and
throughout the study (P <0.0001). Those with more education were less likely to have elevated
symptom scores (P = 0.0007) but more likely to be taking antidepressant medicine (P = 0.002). Non-
Hispanic white participants were less likely than African Americans to have BDI scores ≥11 (P =
0.03), but white participants were more likely to be taking antidepressant medicine than any other
racial/ethnic group (P <0.0001).
CONCLUSIONS—DPP participation was not associated with changes in levels of depression.
Countervailing trends in the proportion of DPP participants with elevated depression symptoms and
the proportion taking antidepressant medicine resulted in no significant change in the proportion with
either marker. The finding that those taking antidepressant medicine often do not have elevated
depression symptoms indicates the value of assessing both markers when estimating overall
depression rates.
Address correspondence and reprint requests to Richard Rubin, PhD, Diabetes Prevention Program Research Group, George Washington
University Biostatistics Center, 6110 Executive Blvd., Suite 750, Rockville, MD 20852. E-mail:dppmail@biostat.bsc.gwu.edu..
*The members of the writing group for the Diabetes Prevention Program Research Group are Richard R. Rubin, PhD; William C. Knowler,
MD, DrPh; Yong Ma, MS; David G. Marrero, PhD; Sharon L. Edelstein, ScM; Elizabeth A. Walker, DNSc, RN; Sanford A. Garfield,
PhD; and Edwin B. Fisher, PhD.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
NIH Public Access
Author Manuscript
Diabetes Care. Author manuscript; available in PMC 2005 December 15.
Published in final edited form as:
Diabetes Care. 2005 April ; 28(4): 830–837.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Abbreviations
BDI, Beck Depression Inventory; DPP, Diabetes Prevention Program; IGT, impaired glucose
tolerance; MET, metabolic equivalent; MDD, major depressive disorder; SSRI, selective serotonin
reuptake inhibitor
Depression is more common among people with diabetes than in the general population (1,
2). The causal relationships between depression and glucose metabolism are not well
understood, but some associations have been documented. People with diabetes who are
depressed have higher HbA1c levels (3), more diabetes complications (4,5), and much higher
general health care costs than people with diabetes who are not depressed (6,7). Treating
depression in people with diabetes may be associated with improved glucose control (8,9), but
this has not been seen in patients with lower HbA1c levels (10,11). Effective treatment is
provided to <25% of depressed diabetic patients (12).
Recent studies suggest that depression and glucose dysregulation may be linked before the
onset of type 2 diabetes. Some suggest that depression could increase a person’s risk of
developing type 2 diabetes (13–15), either by influencing behaviors such as eating and physical
activity or via increased sympathoadrenal and hypothalamic-pituitary-adrenal axis activity
(16,17). The Diabetes Prevention Program (DPP) offered an opportunity to study depression
markers in a population at increased risk for developing type 2 diabetes because they are
overweight and have impaired glucose tolerance (IGT).
The associations among depression, activity level, and weight are not clear. Some have found
a positive association between weight and depression (18–20), though this may be true only
for women (21). Others have reported contrasting findings regarding the association between
activity level and depression (22,23). If changes in activity level and weight are associated with
changes in depression markers, DPP participants in the intensive lifestyle arm could experience
greater changes in these markers than those in the placebo and metformin arms. The effects of
DPP interventions on depression markers could influence the likelihood that interventions
similar to the DPP will be widely adopted.
Some demographic factors, including age, sex, race/ethnicity, and education, appear to be
associated with depression in the general population (1,24–27) and among people with diabetes
(28), although we found no studies of antidepressant medicine use among patients with
diabetes. The large multiethnic DPP cohort offers an opportunity to determine whether the
effects of DPP participation on depression markers vary by demographic factors in a population
with IGT. We found no studies of any depression marker in people with IGT.
In this study, we address the following questions. 1) Did the proportion of DPP participants
with depression markers (elevated symptom scores and antidepressant medicine use) change
during the course of the study? 2) Did these changes differ by treatment arm? 3) Did these
changes differ by participant demographic characteristics? 4) Were these changes associated
with changes in weight or activity level?
RESEARCH DESIGN AND METHODS
The DPP was conducted at 27 centers and involved persons at high risk for developing type 2
diabetes. Methods (29,30) and results (31) have been described in detail elsewhere, and the
protocol is available at http://www.bsc.gwu.edu/dpp. The institutional review board at each
center approved the protocol, and all participants gave written informed consent.
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A total of 3,234 participants enrolled in the DPP, but only 3,187 completed the depression
symptoms questionnaire at baseline. This analysis is based on these 3,187 participants.
Participants were at least 25 years of age, had a BMI of ≥24 kg/m2 (≥22 kg/m2 in Asians), and
a plasma glucose concentration of 95–125 mg/dl (5.3–6.9 mmol) in the fasting state (≤125 mg/
dl in American Indians) and 140–199 mg/dl (7.8–11.0 mmol) 2 h after a 75-g oral glucose load.
Individuals were excluded if in the previous weeks they had taken antidepressant medicines
that might contribute to weight loss, such as bupropion or a selective serotonin re-uptake
inhibitor (SSRI) at more than the lowest usual dose (i.e., >20 mg fluoxetine or the equivalent)
(32). Potential participants were also excluded if they had illnesses or conditions that could
seriously reduce their ability to participate in the study (including major psychiatric disorders)
or were unable to successfully complete the 3-week run-in period, during which participants
took placebo medicines and recorded eating and activity. Recruitment was designed to
randomize approximately half the participants from racial/ethnic minority groups.
Interventions
Eligible participants were randomly assigned to one of three interventions: standard lifestyle
recommendations plus metformin (Glucophage) at a dose of 850 mg twice daily (metformin
arm), standard lifestyle recommendations plus a placebo pill twice daily (placebo arm), or an
intensive lifestyle modification program (intensive lifestyle arm). Goals for participants
assigned to the lifestyle intervention were to achieve and maintain a weight reduction of at
least 7% of initial body weight through a healthy low-fat diet and to engage in physical activity
of moderate intensity, such as brisk walking, for at least 150 min/week (33).
Outcomes
As part of a comprehensive protocol, DPP participants completed the Beck Depression
Inventory (BDI) (34) before randomization and subsequently at each annual visit. Scores for
the BDI were masked to clinic staff, but a question on the BDI concerning thoughts of suicide
was screened by staff during the visit at which the BDI was completed. If the participant’s
response to this question was “I have thoughts of killing myself but I would not carry them
out,” “I would like to kill myself,” or “I would kill myself if I had the chance,” the program
coordinator consulted with the clinic behavioral scientist and/or principal investigator to decide
what action to take.
Participants brought all prescription medicines to each clinic visit, from which the current use
of antidepressant medicines was assessed. We report follow-up through July 2001, after which
the primary results were announced and the interventions unmasked. This was 4 months longer
than the results reported previously (31), resulting in a total mean follow-up of 3.2 years per
participant.
We measured depression in three ways: BDI scores ≥11, current use of antidepressant
medicines, and either BDI score ≥11 or current use of antidepressant medicines. We included
the third measure because we wanted an estimate of all participants who could be considered
depressed, regardless of whether they were treated. Other researchers have chosen BDI scores
ranging from 10 to 16 to define depression (35–38), generally as a function of the importance
placed on depression recognition. We chose a score toward the low end of the severity range
as our symptom threshold because we believed few severely depressed participants would pass
the screening process for eligibility in the DPP.
Self-reported levels of leisure physical activity were assessed annually with the Modifiable
Activity Questionnaire (39). Physical activity level was calculated as the product of the duration
and frequency of each activity (in hours per week), weighted by an estimate of the metabolic
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equivalent (MET) of that activity, and summed for all activities performed, with the result
expressed as the average MET hours per week for the previous year.
Analysis
Demographic factors (age at randomization, sex, race/ethnicity, and education) were examined
for differences in the proportion of participants with depression markers at entry to the study
using Pearson’s χ2 test. Multiple logistic regression modeling with all demographic variables
as covariates was performed to rule out confounders. Repeated-measures modeling using
generalized estimating equations (40) was used to evaluate trends in the proportion of
participants with depression markers over time, as well as differences in time trends among
treatment arms or by participant demographic factors. Generalized estimating equations were
also used to evaluate the association between weight loss, leisure activity change, and having
depression markers. Type III score test was used for the P value, and Wald CI was reported.
SAS was used for all analyses (version 8.2; SAS Institute, Cary, NC).
RESULTS
Table 1 shows demographic characteristics and depression marker levels for DPP participants
at randomization. Among the 3,187 participants, 328 (10.3%) had BDI scores indicating at
least mild depression (≥11), 86 (2.7%, data not shown) had BDI scores indicating moderate to
severe depression (≥16), and 181 (5.7%) were taking antidepressant medicines. On entry to
the study, only 29 (0.9%) DPP participants had both depression markers.
We found strong baseline associations between depression markers and all demographic factors
except age (Table 1). At baseline, controlling for other demographic factors, men were less
likely than women to have BDI scores ≥11 (P = 0.002), less likely to be taking antidepressant
medicines (P < 0.0001), and less likely to have either depression marker (P < 0.0001).
Participants with more education were less likely to have elevated BDI scores (P < 0.0001)
and more likely to be taking antidepressants (P = 0.05). Race/ethnicity was associated with
both elevated BDI scores (P = 0.0001) and antidepressant medicine use (P < 0.0001). Pairwise
comparison (data not shown) found that non-Hispanic white participants were less likely to
have elevated BDI scores than African-American, Hispanic-American, and American-Indian
participants (P < 0.006) and more likely to take antidepressant medicines than those in any
other racial/ethnic group (P < 0.004, except P < 0.05 compared with American Indians and
Asians). Hispanic-American participants were more likely to take antidepressants than
African-American participants (P = 0.01). At the end of study, 93% of participants remained
active, and this was not associated with baseline depression marker status.
Changes in depression markers during the DPP
The proportion of DPP participants with BDI scores ≥11 decreased during the study (from
10.3% at baseline to 8.4% at year 3, P = 0.0016), whereas the proportion using antidepressant
medicines increased (from 5.7% at baseline to 8.7% at year 3, P < 0.0001). The proportion of
participants who had at least one of these two markers did not change significantly over time,
reflecting the countervailing effects of the two component measures. These changes are shown
by treatment arm in Table 2 for both sexes. There was no significant interaction between DPP
treatment arm and any of these time trends for either sex, indicating that the trends were similar
for the three treatment arms, although at the 3rd year of follow-up there were marginally
significant treatment arm differences in the proportion of female participants with either
depression marker (P = 0.0635). The rate in the intensive lifestyle arm was lower than that in
the placebo arm at that point (P < 0.02). In a separate analysis (data not shown), weight loss
during the DPP was associated with a small but significant reduction in the risk of elevated
depression (odds ratio [OR] 0.975/kg [95% CI 0.960–0.990], P = 0.002), and increased leisure
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activity was associated with a small but significant reduction in the risk of elevated symptoms
(0.960/5 MET h/week [0.920–1.001], P = 0.012), a trend toward reduced antidepressant use
(0.976/5 MET h/week [0.950 –1.002], P = 0.058), and a small but significant reduction in either
marker (0.965/5 MET h/week [0.939 – 0.992], P = 0.002). There were no significant
interactions between these trends and treatment arm.
Figure 1 shows changes in depression markers during the course of the DPP as a function of
baseline depression marker status. Figure 1A shows that the majority (n = 2,707) of participants
had neither marker at baseline; by the year 3 follow-up, ~5% of those participants had BDI
scores ≥11, and a similar proportion were taking antidepressant medicines. Participants who
had baseline BDI scores ≥11 (Fig.1B) were more likely to start taking antidepressant medicines
during the DPP than participants with lower baseline BDI scores (Fig. 1A; OR 2.63, P <
0.0001). Most participants who had BDI scores ≥11 at baseline did not have elevated scores
by the year 1 follow-up (Fig. 1B and D), regardless of baseline antidepressant medicine use.
Similarly, many participants who were taking antidepressant medicine at baseline were no
longer taking it by the year 1 follow-up, regardless of baseline BDI score (Fig. 1C and D).
Figure 2 shows that during the DPP, antidepressant medicine use increased more among male
than among female participants (P = 0.009). There were also significant interactions between
trends in the proportion with either depression marker and both race/ethnicity (P < 0.0001) and
education (P = 0.002). The proportion with either depression marker increased among non-
Hispanic whites relative to other racial/ethnic groups and among those with ≥17 years of
education relative to those with less education.
CONCLUSIONS
Effects of DPP participation on depression markers
On entry to the DPP, 10.3% of participants had elevated depression scores. In other studies of
national samples, 6.1% of individuals without diabetes and 9.3% of individuals with diabetes
had major depressive disorder (MDD) based on the results of structured clinical interviews
(1,24). Structured clinical interviews have been shown to identify fewer cases of depression
than screening tools like the BDI (2), so the proportion of DPP participants who would have
qualified for a diagnosis of MDD based on symptoms was probably close to that for the general
population of people without diabetes. We found that in addition to the 10.3% of participants
who entered the DPP with elevated BDI scores, 5.7% were taking antidepressant medicine,
and 0.9% had both depression markers.
During the course of the study, the proportion of participants taking antidepressant medicines
went up while the proportion with elevated depression symptoms went down, leaving the
proportion of DPP participants with either depression marker unchanged. Changes over time
in the proportion of DPP participants with either depression marker did not vary significantly
by treatment arm for participants of either sex.
If we had considered only symptoms, we might have concluded that the DPP interventions
resulted in decreased depression. Including antidepressant medicine use as a depression marker
suggests no effect of the DPP on the prevalence of depression. Increased antidepressant use
by DPP participants appears to parallel trends in the general population. During the decade that
ended in 1997, antidepressant medicine use in the U.S. tripled (27) and rates presumably
continued to rise during the years of the DPP, which ended in 2001. This dramatic increase in
antidepressant medicine use was substantially fueled by the popularity of selective serotonin
reuptake inhibitors (SSRIs). SSRIs were not available in 1988, but by 1997 they were
prescribed for 58% of all patients treated for depression, including those treated without
medication (27). DPP participation might have also encouraged health care–seeking behavior
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or resulted in medical referrals, either of which could lead to greater use of antidepressant
medicines.
Treatment arm differences in depression markers during the study/association between
depression markers and changes in weight and activity
We found no significant interactions between depression marker time trends and DPP treatment
arm for either men or women, although at annual visits for years 2 and 3 the proportion of
participants in the intensive lifestyle arm with either depression marker was lower than that in
the placebo arm. Weight loss was associated with a small but significant reduction in the
likelihood of elevated depression symptoms, and increased leisure activity had similar
associations with all depression markers. The magnitude of these associations was small, so it
is difficult to estimate their clinical significance. The fact that these associations did not differ
by treatment arm suggests that they are not unique to participants in a structured lifestyle
intervention.
Changes in depression markers during the study as a function of baseline depression marker
status
Among DPP participants not taking antidepressant medicine at randomization, those with
elevated baseline BDI scores were more likely to start taking these medications during the
study, but only a small minority of those with elevated baseline scores began taking these
medicines while they were in the DPP. While this suggests that many participants who might
have benefited from antidepressant medicines were not receiving them, we also found evidence
that elevated BDI scores were a transitory phenomenon, perhaps not requiring treatment: most
participants with elevated baseline BDI scores had lower scores by their year 1 follow-up,
regardless of their baseline antidepressant medicine use.
Association between demographic factors and depression markers
Other studies have reported that depression is less common among men, both in the general
population (24) and among those with diabetes (1,28), and we found that male DPP participants
were less likely to have elevated symptom scores throughout the study. A population-based
study reported relatively small sex differences in antidepressant medication rates among
psychiatric patients (41). In contrast, men in the DPP were less likely to take antidepressant
medicines throughout the study. Differences in provider treatment practices or differences in
insurance coverage for medication costs could account for differences in findings.
Other studies have reported that depression is less common among those with more education
in the general population (24–26) and perhaps also among people with diabetes who have more
education (28), although a population-based study that included people with diabetes found no
association between depression and education (1). We found that throughout the study,
participants with more education were less likely to have elevated depression symptom scores
and more likely to be taking antidepressant medicines, although the proportion with either
marker increased during the course of the study among those with the most education, whereas
it remained unchanged among those with less education.
Some studies in the general population and a population-based study that included people with
diabetes found no differences in depression markers among non-Hispanic whites, African
Americans, and Hispanic Americans (1,25,26), although one study in the general population
reported lower rates of lifetime MDD among African Americans than among non-Hispanic
whites or Hispanic Americans (24). We found that throughout the DPP, non-Hispanic white
participants were less likely to have elevated scores than African Americans and Hispanic
Americans and that they were more likely to be taking antidepressant medicine than any other
racial/ethnic group. During the course of the study, the proportion with either depression
Page 6
Diabetes Care. Author manuscript; available in PMC 2005 December 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
marker increased among non-Hispanic whites but remained unchanged among other racial/
ethnic groups.
Strengths and limitations of the current study
Strengths of the current study include the large multiethnic population, including groups in
which depression has rarely been studied, the definitive identification of IGT, and the fact that
data were collected regarding antidepressant medication and depression symptoms.
Limitations include the fact that the study cohort is probably not representative of all
individuals with IGT because self-selection and screening procedures make it very likely that
severely and even moderately depressed individuals were under-represented. Also, we did not
confirm that all patients using antidepressants were taking them for depression. These
medicines are prescribed to treat other conditions. Some SSRIs are used to treat panic disorder,
obsessive compulsive disorder, post-traumatic stress disorder, social anxiety disorder, and
bulimia nervosa (42), but patients with these disorders probably represent a small proportion
of those taking SSRIs. On entry to the DPP, 68% of participants taking antidepressants were
taking SSRIs. At the 3rd year follow-up, this proportion was 76%. Tricyclic antidepressants
are sometimes prescribed for relief of neuropathic symptoms in patients with diabetes, but DPP
participants did not have diabetes at the outset of the study.
Implications
The current study suggests that it is possible to engage willing participants in an intensive effort
to prevent or delay the development of type 2 diabetes without increasing depression. In fact,
we found that participants who were more active or who lost weight also had small but
significant reductions in their risk for some depression markers during the course of the study,
independent of their treatment arm. These findings reinforce earlier reports that activity and
weight are associated with depression (18–20,43,44), and they suggest a positive psychological
impact of intensive efforts to prevent type 2 diabetes.
Our study also reveals relatively low levels of reported depression treatment among most racial/
ethnic minorities and among those with less education. We found some signs that these
differences diminished during the course of the study, but they remained large and should be
further investigated and addressed for reasons of equity and because depression in people with
IGT may be associated with negative physical health outcomes, as in people with diabetes.
The current findings offer guidance for future research. Our finding that there was essentially
no overlap between the group of participants with BDI scores ≥11 and those taking
antidepressant medicine reinforces the importance of considering the latter as a marker of
depression. Estimates of depression rates based on either BDI or medication alone are likely
to be too low. The lack of overlap between those with elevated symptoms and those taking
antidepressant medicine also raises questions about possible differences between the two
groups in health outcomes and how these outcomes might differ from those for patients
receiving psychotherapy for depression. Considering both depression markers also provides a
basis for understanding the clinical complexity of patients treated for depression. Patients who
are positive for both markers likely have partially treated depression, those who take
antidepressant medicine but do not have elevated symptoms have fully treated depression or
are taking antidepressants for other indications, patients with elevated symptoms who are not
taking antidepressant agents have untreated depression or depression that has not responded
to psychotherapy, and patients with neither depression marker are not depressed or their
depression has been treated successfully with psychotherapy.
We did not collect data on psychotherapy in this study. Future studies should do so. Future
studies should also determine with certainty that antidepressant medicines are being taken to
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treat depression rather than other conditions, and they should include subjects who are more
representative of the population of individuals with IGT than those enrolled in the DPP.
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Figure 1.
Change in two depression markers (BDI ≥11 and taking antidepressant medicine) by baseline
depression status. A: Participants who were negative for both depression markers at
baseline. B: Participants with baseline BDI ≥11 who were not taking antidepressant
medicine. C: Participants with BDI <11 and taking antidepressant medicine. D: Participants
who were positive for both depression markers.
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Figure 2.
Time trend in depression markers by demographic factors sex (A), race/ethnicity (B), and
education (C). Time trend in antidepressant medication varied by sex (A, P = 0.009). Time
trend in either depression marker use varied by race/ethnicity (B, P < 0.0001) and education
(C, P = 0.001).
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